The Antibiotics Exist —The System Cannot Deliver Them
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on.
City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders.
presented by
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer and AbbVie.
Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building
Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset.
Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity
Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals.
What Corporate Venture Funds Get Wrong about Strategic Value
Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures.
TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance
Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO cash for mid-stage testing of a next-generation hypertension drug.
What Life Sciences Commercial Teams Can Learn from Digital Health
The pace of change in digital innovation has exposed the ever-widening gap between digital health and Pharma commercial teams. As a result, Pharma is missing out on its ability to significantly improve its commercial model, by focusing on efficiencies vs. truly reinventing.
Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road
Caribou Biosciences is stopping work on its two remaining cancer cell therapies and exploring strategic alternatives for the business. The move follows the CRISPR biotech company’s failure to secure financing for its clinical trial plans.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
From Distributor to Disruptor: Amazon’s Healthcare Flex
No longer satisfied with buying pharmacies and clinics, it seems intent on owning the healthcare journey, and perhaps redrawing pharma’s commercialization map.
Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition
Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi’s second big rare disease move this year, following the acquisition of global rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma.
Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System
While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all.
Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during the European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder.
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because Dupixent faces patent expiration in 2031.